Tagged with Accord

Belgium Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities to develop, manufacture and sell medicines.   Despite representing only a mid-size marketplace from an in-country commercial perspective, the comparatively…

Belgium Accord Healthcare’s Stefano Christoffersen outlines the strategy that has led to Accord becoming one of the fastest-growing generics and biosimilar companies in Europe, why the firm has chosen to focus on the hospital generics niche, and his hopes for continuing to meet unmet patient need in Belgium in the coming…

Italy Digitalisation has become a buzz word in in the global life sciences sector. In Italy, digital transformation has taken on special significance as one of the principal goals encompassed in the country’s National Recovery and Resilience Plan and a priority within its healthcare modernisation plans.   Novel solutions came out…

Europe Accord Healthcare’s Massimiliano Rocchi, Associate Vice President, Italy & Greece, explains the Italian generics market’s increased level of competition and Italian payers’ post-COVID willingness to accept the Most Economically Advantageous Tender (MEAT) concept. He also discusses the company’s move towards digitalisation and its ambition to build a bridge between the…

Spain Accord’s Marc Comas highlights the company’s presence in Spain with leading oncology products, three biosimilars and investment in specialty pharma. He shares his views on the COVID pandemic, the future of the supply chain, the importance of Spain, Barcelona’s attractiveness for the pharma industry, and explains why Accord will be…

Romania While the dismal regulatory environment in Romania has negatively affected the innovators with the uncertain and lengthy regulatory approval timelines as well as the dreaded ‘clawback tax’ doubling over the past decade, the generics sector has argued that they are the ones that have borne the brunt of unfavourable industry…

Romania Daniel Bran, GM of Accord Romania reveals that finding the right talent has been one of the most challenging and rewarding milestones in building the affiliate from the ground up. He shares his insights on what is driving Accord’s growth and how launching nearly 20 new products a year has…

Spain Marc Comas, managing director of Accord Healthcare Iberia, highlights the footprint of the company as the leading generics and biosimilars player in the Spanish hospital sector and how his early strategy when founding the affiliate has set them up for long-term success. Furthermore, he points out the dynamics of the…

UK Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive double-digit market share in the UK, putting Accord firmly on track to attain their goal of becoming a top 5…

Poland As east area director for the vast CEE market, Pawel Mazur explains how Accord Healthcare has gone from strength to strength in Poland, with the intention of becoming a top five generics company in the country by 2021. He also touches on the importance of a high-performing team, the exciting…

Canada Michel Charbonneau, executive VP at Accord Healthcare Inc. touches upon the rapid evolution of the Canadian affiliate over the past five years, and the company’s commitment to bringing high-quality, innovative, affordable generics to patients. He furthermore expresses his hopes for collaboration between generic players in the Canadian pharmaceutical industry in…

Austria Siegfried Leitner, general manager of Accord Austria and Germany, and CEO and co-founder of A-med, provides an insight into the early years of his Accord affiliate and how it was able to establish itself in Austria and elaborates on the current portfolio of Accord in Austria. He also provides an…